OncoSec Initiates a Triple Combination Immunotherapy Trial for Squamous Cell Head and Neck Cancer

 OncoSec Initiates a Triple Combination Immunotherapy Trial for Squamous Cell Head and Neck Cancer

OncoSec Initiates a Triple Combination Immunotherapy Trial for Squamous Cell Head and Neck Cancer

Shots:

  • The triple combination study, TRIFECTA involves the assessing of TAVO, Epacadostat & Keytruda vs Keytruda as monothx/keytruda + epacadostat as combination therapy in 35 patients with squamous cell carcinoma head and neck (SCCHN) cancer, with its 1EP as overall response rate (ORR) by RECIST v1.1 
  • The TRIFECTA study will be conducted by UCSF Helen Diller Family Comprehensive Cancer Center, with its expected result as improvement in anti-PD-1 monotherapy durable remission response rate of 13-16%. The cost of the trial will be shared with Merck and Incyte Corporation
  • TAVO (tavokinogene telseplasmid) enables intra tumoral delivery of DNA-based IL-12 targeting tumor cells. Epacadostat is an IDO inhibitor, enables the T-Cell modulation. Keytruda (pembrolizumab) is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activates the T lymphocytes

Click here to read full press release/ article | Ref: OncoSec | Image: Happy Hour Headshot

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post